Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

Author: , BatyckyRichard, FernandezHubert H, HauserRobert A, IsaacsonStuart H, LeWittPeter A, LewMark, Lopez-ManzanaresLydia, OhCharles, PahwaRajesh, PourcherEmmanuelle, RudzínskaMonika, Saint-HilaireMarie, SedkovAlexander, WatersCheryl

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and efficacy of CVT-301, an inhaled levodopa powder, for treating Parkinson's disease during "off periods" when oral levodopa is less effective.
Paper Details　
Original Abstract of the Article :
Patients with Parkinson's disease chronically treated with levodopa commonly have delayed or unpredictable onset of its benefits after oral intake. In this study, we assessed the safety and efficacy of CVT-301, a self-administered levodopa oral inhalation powder, for the treatment of patients with P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1474-4422(18)30405-8

データ提供：米国国立医学図書館（NLM）

Levodopa Inhalation: A Breath of Fresh Air for Parkinson's Disease

My research often takes me to the heart of [neurology], where I explore the complexities of [Parkinson's disease] and the ongoing search for effective treatments. This study investigates the safety and efficacy of [CVT-301 (levodopa inhalation powder)] for managing [motor function] in patients with Parkinson's disease experiencing 'off periods,' a time when the effects of oral levodopa have worn off.

A New Breath of Relief for Parkinson's Patients

The study assessed the potential benefits of [CVT-301 (levodopa inhalation powder)] for Parkinson's patients experiencing 'off periods.' The research found that [CVT-301 was safe and effective in improving motor function] during these challenging periods, suggesting that this novel approach could provide a valuable therapeutic option for patients with Parkinson's disease.

Navigating the Desert of Parkinson's: Finding Relief Through Inhalation

Imagine a camel traversing a vast desert with unpredictable sandstorms and shifting landscapes. The camel's movements may be affected by the ever-changing terrain. Similarly, patients with Parkinson's disease experience challenges with movement due to the progressive degeneration of brain cells. This research explores the potential of [CVT-301 (levodopa inhalation powder)] to provide a much-needed breath of relief for Parkinson's patients, helping them navigate the challenges of their condition with greater ease.

Dr.Camel's Conclusion

This research represents a significant advancement in the treatment of Parkinson's disease. The development of CVT-301 (levodopa inhalation powder) offers a promising new approach for managing motor function during 'off periods,' potentially improving the quality of life for patients with this debilitating condition. This research reminds us that even in the face of complex neurological disorders, we can find innovative ways to improve patient outcomes and provide hope for a better future.

Date :
  1. Date Completed 2020-06-08
  2. Date Revised 2020-06-08
Further Info :

Pubmed ID

30663606

DOI: Digital Object Identifier

10.1016/S1474-4422(18)30405-8

Related Literature

Article Analysis
・Effects of levodopa oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.